Blog | Life Sciences | Valuation

Is there still life in the UK Life Science Market?

The UK life science market remains active and resilient, but the sector is entering a more nuanced phase as global and domestic pressures reshape the landscape. Over the past decade, life sciences have become a cornerstone of the UK’s growth strategy, with the government identifying the sector as a priority in its ten-year industrial plan. This policy focus is matched by tangible economic impact: industry clinical trials now contribute over a billion pounds annually to NHS revenue, support thousands of jobs, and underpin a thriving research ecosystem. The UK’s regulatory environment has evolved rapidly, with streamlined approvals and digital transformation programmes halving clinical trial setup times and making the country increasingly attractive for global research and development. The NHS’s integration with research institutions and industry further strengthens the sector’s foundation, supporting both innovation and improved health outcomes.

The real estate landscape for life sciences has expanded at an unprecedented pace, with more than 100,000 square metres of new space delivered in 2024 and forecasts suggesting this could quadruple by the end of 2025. This growth has been fuelled by a post-pandemic surge in investor interest, as the sector demonstrated its resilience during economic downturns and its critical role in public health. However, there are signs of a maturing market: some high-profile projects have been paused or reconsidered, and investors are becoming more selective, focusing on quality, location, and long-term demand drivers. The “Golden Triangle” of London, Oxford, and Cambridge remains the epicentre of UK life sciences, anchored by world-class universities and research institutions. Yet, these cities face constraints such as high housing costs, limited land, planning difficulties, and infrastructure challenges, prompting both government and private sector initiatives to unlock further growth—such as major transport investments and planning reforms. Regional centres like Manchester, Bristol, and Liverpool are also emerging as significant hubs, leveraging strengths in genomics, digital health, and pharmaceutical manufacturing, and helping to spread economic benefits and create new opportunities for talent and investment across the UK.

A comparison with the US market provides important context. The US, long considered the global leader in life sciences, has recently experienced a dramatic shift. After years of rapid expansion and near-zero vacancy rates, a construction boom has led to oversupply in major US markets, with double-digit vacancy rates now commonplace and new construction expected to slow sharply. The sheer scale of the US market—Boston alone has over 4.6 million square metres of lab space—means that when supply outpaces demand, the impact is significant. Investor caution has increased, with some projects delayed or cancelled, and a “flight to quality” is expected as only the best-located, purpose-built facilities attract tenants. Broader industry pressures, such as rising R&D costs, regulatory changes, and global economic uncertainty, have also contributed to a more challenging environment. In contrast, the UK market is younger and has not yet faced the same oversupply issues, largely due to slower deliverability, planning constraints, and the limited availability of land and infrastructure in key clusters. These constraints, while challenging, have helped maintain a favourable supply-demand balance for landlords and developers.

Looking ahead, the UK life science market is set to benefit from several long-term trends: an ageing population, advances in medical technology, the rise of AI in drug discovery, and the increasing importance of national supply chain resilience. The sector’s resilience, policy support, and expanding geographic reach position it well for continued growth, even as the market evolves. Investors are particularly drawn to the UK life sciences sector for its strong fundamentals: a world-class academic and research base, a collaborative regulatory environment, and a robust talent pool. The UK’s leadership in clinical trials, high levels of public trust in research, and the integration of the NHS with industry and academia create a unique ecosystem that supports innovation and commercialisation. However, the sector is not without risks. Funding challenges, rising construction and operational costs, and the potential for future oversupply—especially if the current pipeline is delivered without corresponding demand—mean that caution is warranted. In summary, while the UK life science market is not immune to global pressures and faces its own set of constraints, there is still considerable life in the sector. Strong fundamentals, policy support, and a growing national footprint ensure its continued relevance, resilience, and attractiveness to investors, but success will increasingly depend on quality, innovation, and the ability to adapt to a changing global landscape.

More from this Author

09/06/2025 Blog | Diversity and Inclusion

What pride means to me, Gareth Hosgood


13/03/2025 Podcast | Charity | Fundraising

Beyond Bricks: Building Futures with The Cycle Charity


29/07/2022 Blog | Landlord | Offices

Why landlords have turned to flexible offices to boost values



Related Insights

 Terrifying Statistics or Development Opportunities???
Blog 17/07/25

Terrifying Statistics or Development Opportunities???

Development | Valuation

Chronic under-delivery of new housing will likely continue to act as a support for pricing in the face of consistent demand, ...

Leasehold, Commonhold & Rental Reforms - key changes & their potential impact
Blog 27/03/25

Leasehold, Commonhold & Rental Reforms - key changes & their potential impact

Valuation | Leasehold & Freehold Reform

The property landscape in England and Wales is undergoing significant changes, with the introduction of new legislation aimed...

Podcast: With £1billion of sales at auction three Allsop experts say how they would invest £10m in 2025
Podcast 23/01/25

Podcast: With £1billion of sales at auction three Allsop experts say how they would invest £10m in 2025

Commercial Auction | Residential Auction

Want to know more or would simply like some advice? We hope you find this podcast useful. If you want to know more about topi...

Fit for Purpose: How UK Gyms Are Adapting to Changing Consumer Demands
Blog 25/11/24

Fit for Purpose: How UK Gyms Are Adapting to Changing Consumer Demands

Valuation | Leisure

The gym sector is considered one of the strongest leisure markets with a growing emphasis on a healthy lifestyle change in so...